PMCCPMCCPMCC

Search tips
Search criteria 

Advanced

 
Logo of wjgLink to Publisher's site
 
World J Gastroenterol. Jul 7, 2012; 18(25): 3196–3200.
Published online Jul 7, 2012. doi:  10.3748/wjg.v18.i25.3196
PMCID: PMC3391755
Can zinc enhance response interferon therapy for patients with HCV-related liver disease?
Toru Ishikawa
Toru Ishikawa, Department of Gastroenterology and Hepatology, Saiseikai Niigata Daini Hospital, Niigata 950-1104, Japan
Author contributions: Ishikawa T contributed solely to this review.
Correspondence to: Toru Ishikawa, MD, PhD, Department of Gastroenterology and Hepatology, Saiseikai Niigata Daini Hospital, 280-7 Teraji, Niigata 950-1104, Japan. toruishi/at/ngt.saiseikai.or.jp
Telephone: +81-25-2336161 Fax: +81-25-2338880
Received August 17, 2011; Revised September 24, 2011; Accepted October 11, 2011.
Patients with liver disease may be at risk of zinc depletion. Zinc supplementation has been shown to contribute to inhibition of liver fibrosis and improvement in hepatic encephalopathy. However, little is known about the anti-inflammatory effect of zinc on hepatitis C virus (HCV)-related chronic liver disease. The standard of care for chronic HCV has improved markedly since the approval of interferon (IFN) therapy more than a decade ago. Over the past 20 years, IFN therapy has improved to more effectively eliminate the virus, progressing from single IFN therapy to combination therapy with ribavirin (RBV) and finally to pegylated IFN (PEG-IFN) therapy. However, even combined therapy with PEG-IFN and RBV for 48 wk is unable to eliminate the virus in some 40% of hepatitis C cases, particularly those with genotype 1b and high viral load. Treatment options for patients who have relapsed or are refractory to treatment with PEG-IFN and RBV therefore need to be critically assessed. This paper overviews the relationship between chronic liver disease and zinc metabolism.
Keywords: Chronic hepatitis C, Zinc, Interferon therapy
Abnormal metal metabolism, which is related to liver disease, has long been a subject of pathological study, particularly storage diseases such as iron metabolism in hemochromatosis[1] and copper metabolism in Wilson’s disease[2].
As nutrition science has advanced, it has recently been pointed out that trace metallic elements in blood play essential roles, and abnormal metal metabolism involving metal deficiency in various diseases has been studied.
Zinc is an essential trace element in the human body, with approximately 2 g distributed throughout the body of a healthy adult, including many organs[3-5]. In vivo, this element stimulates the activity of as many as 300 metal enzymes and metal-activated enzymes, and is crucial for nucleic acids and protein metabolism. Zinc plays an important role in the activity of many enzyme proteins, and a deficiency of zinc causes various pathologic disorders in the human body.
Regarding zinc metabolism abnormality in liver disease, in 1951 Vikbladh pointed out that the zinc content in serum was low in the case of various liver diseases[6], and conjectured that serum contains albumin loosely bound to zinc and globulin firmly bound to zinc, and that the albumin is associated with a lower zinc content. In 1957, Bartholomay et al[7] claimed that hypozincemia in liver disease might be associated with increased urinary zinc excretion. In 1979, Sullivan et al[8] pointed out that decreased zinc absorption was observed in cases of alcoholic cirrhosis, and in 1988, Grüngreiff et al[9,10] reported that poor zinc absorption was observed in cases of non-alcoholic cirrhosis.
It is known that among liver disease cases, those with chronic hepatitis C show lower zinc concentrations in blood as their pathologic condition worsens from chronic hepatitis, to compensated cirrhosis, to decompensated cirrhosis, to hepatocellular carcinoma (HCC). Serum and hepatic zinc concentrations are decreased in chronic liver diseases, and zinc depletion has been suggested to be a cause of liver fibrosis[11,12]. Particularly, cases with liver failure[13] or cases of HCC[14,15] are known to show conspicuous hypozincemia, and zinc supplementation therapy improves liver disease.
A study of the relationship of the existence of hepatitis C virus (HCV) with zinc concentration in serum suggested that zinc concentration was not related to HCV genotypes or HCV-RNA values, and thus the existence of HCV did not affect the serum zinc concentration. However, it was reported that the serum zinc concentrations of untreated asymptomatic carrier (ASC) cases were significantly lower than those of healthy people[16]. From this report, it can be inferred that the existence of HCV may be related to the serum zinc concentration even if the former does not directly affect the latter.
It has recently been reported that nonstructural 3 proteinase[17-20], which is involved in the replication of HCV, is a zinc-containing enzyme, and that the nonstructural 5A protein is a zinc metalloprotein[21]. Accordingly, it is necessary to examine and control the serum zinc concentration when treating cases of refractory chronic hepatitis C. In addition, in ASC cases, their progress may need to be observed by monitoring the serum zinc concentration and other means.
It has been reported that zinc in blood is closely related to hepatic fibrosis in cases of liver disease. It has also been reported that drug therapy or gene therapy that increases the serum zinc concentration can inhibit the progress of hepatic fibrosis[22]. Many studies, including those noted above, suggest that pathologic conditions of the liver are closely related to zinc in blood. However, although there have been basic researches, its relationship with hepatic fibrosis has not been clinically studied.
Some 60% to 70% of cases of hepatitis C progress to chronic hepatitis, and then to cirrhosis and hepatocellular carcinoma over 20 years to 30 years. Following the 1986 report of Hoofnagle et al[23] on the effects of interferon (IFN) on HCV infection in patients with chronic hepatitis, IFN therapy has been employed throughout the world to treat chronic hepatitis C. The treatment of choice for chronic hepatitis C is antiviral therapy using IFN[24,25].
In Japan, many cases of hepatitis C have been treated with IFN since 1992, when treatment using IFN drugs became covered by the public health insurance system. IFN monotherapy, which was used initially, successfully resulted in low sustained HCV-negative condition of all cases treated[26]. Sustained virological response (SVR) was gained in merely 6% of patients with HCV-1b in high viral loads when the practice of administering a 6-mo regimen of natural IFN was started in 1992; it increased to 20% with the 6-mo regimen of standard IFN combined with ribavirin (RBV) implemented in 2001[27,28]. Finally, the introduction of the 12-mo regimen of pegylated IFN (PEG-IFN) and RBV approved in 2004 achieved SVR in 50%[29,30].
The viral factors that affect the effectiveness of IFN therapy include HCV genotype and HCV-RNA quantity, and the host factors that do so include the histological condition of the liver, age and degree of fatness.
Generally, genotype Ib virus is more resistant to IFN than genotype IIa or IIb viruses. In Japan, genotype Ib in high viral loads accounts for more than 70% of HCV infections, making it difficult to treat patients with chronic hepatitis C[27,28].
With regard to the effect of the combination therapy of oral administration of zinc with IFN for chronic hepatitis C, Nagamine et al[31] reported on the roles of zinc and metallothionein in IFN-α therapy for hepatitis C in 1997. Takagi et al[32] treated 68 cases of chronic hepatitis C with genotype Ib virus of an HCV-RNA quantity of at least 100 Kcopy/mL with a dose of 10 million units of IFN-α once daily for four weeks, and then the same dose three times weekly for the subsequent 20 wk, by intramuscular injection. They combined the IFN administration with an oral dose of 150 mg of polaprezinc (Promac;Zeria Pharmaceutical, Company Ltd., Tokyo, Japan) daily (equivalent to 34 mg of zinc) in 32 of the 68 cases. The effects of the treatment were evaluated six months after completion, with the criteria of complete response (CR) for disappearance of HCV-RNA and normal alanine aminotransferase (ALT) levels; incomplete response (IR) for HCV-RNA that did not disappear, but normal ALT levels; and non-responder for other cases. The IFN monotherapy group (IFN) was compared with the IFN and zinc combination group (IFN + Zn) in terms of those criteria, with the following results. The IFN group showed CR: 11.1% (4/36) and IR: 11.1% (4/36), totaling 22.2% (8/36), while the IFN + Zn group showed CR: 37.5% (12/32) and IR: 18.8% (6/32), totaling 56.3% (18/32). Thus, they concluded that the zinc combination group had a significantly higher effective rate[32].
Murakami et al[33] treated cases of chronic hepatitis C with a high virus quantity of genotype Ib with the PEG-IFN/RBV therapy, and analyzed the proportion of cases that became HCV-RNA negative after eight weeks of treatment by using groups with and without combination with zinc administration with an oral dose of 150 mg of polaprezinc (containing 34 mg of zinc) daily. They reported that the proportion of cases in whom ALT lowered to 35 U/L or less by the eighth week was 91% (10/11) in the zinc combination group and 58% (7/12) in the non-zinc administration group; however, the proportions of cases that became HCV-RNA negative were 18% (2/11) and 25% (3/12) respectively, showing no significant difference. Furthermore, they continued to observe the cases, and reported that all the cases (9/9) in the group with combination with zinc administration and 67% (8/12) of the cases in the group without combination with zinc administration showed normal ALT levels after 24 wk, and that all the cases (7/7) in the group with zinc and 60% (6/10) of the cases in the group without zinc did so after 48 wk. Interferon therapy for chronic hepatitis C has improved in many ways such as combination with ribavirin, and the rate of virus disappearance resulting from such therapy has increased conspicuously in comparison with the initial results. This therapy now achieves an SVR of approximately 50% even for cases with a high virus quantity of genotype Ib, and a viral clearance rate of nearly 90% for other cases. However, this therapy has shown poor results for cases with severe hepatic histological fibrosis or thrombocytopenia, or for elderly patients, so its combination with zinc administration should be attempted in refractory cases.
In cirrhosis, the quantity of hydroxyproline in liver tissues increases while that of zinc decreases. Boyett et al[34] reported that the concentration of zinc per unit nitrogen not derived from collagen was correlated with the concentration of zinc in liver tissues. Himoto et al[35] examined the effects of zinc administration on inflammatory activity and fibrosis of the liver in patients with HCV-related chronic liver disease (CLD). Treatment with polaprezinc significantly decreased serum aminotransferase levels (aspartate aminotransferase: 92 ± 33 IU/L vs 63 ± 23 IU/L, P = 0.0004; ALT: 106 ± 43 IU/L vs 65 ± 32 IU/L, P = 0.0002), whereas alkaline phosphatase levels were significantly increased (305 ± 117 IU/L vs 337 ± 118 U/L, P = 0.0020). There was a tendency toward a decrease in serum type IV collagen 7S levels after treatment with polaprezinc. However, administration of polaprezinc did not affect peripheral blood cell counts, other liver function tests, or HCV-RNA loads. These findings suggest that polaprezinc exerts an anti-inflammatory effect on the liver in patients with HCV-related CLD by reducing iron overload.
Furthermore, Matsuoka et al[36] reported that zinc supplementation improves the outcome of chronic hepatitis C and liver cirrhosis. Takahashi et al[37] investigated the effect of oral zinc supplementation on liver fibrosis in patients with advanced chronic liver disease. The serum levels of type IV collagen and the activity of tissue inhibitors of metalloproteinase-1 were significantly reduced. This suggests that oral zinc supplement therapy is safe and may be a novel and useful strategy for antifibrosis therapy in patients with early liver cirrhosis.
Generally, the oxidative stress is high in hepatitis patients, and significant correlations among HCV-RNA. Oxidant stress is a significant feature of hepatitis C infection[38]. There is evidence that the production of free radicals increases while anti-oxidant defense decreases significantly in all types of liver damage. Alongside the direct effect of the HCV core protein, hepatocellular iron accumulation and the production of reactive oxygen species associated with the immune response are considered to be of crucial significance for the creation of oxidative stress in chronic HCV. Mitochondrial effects may contribute to liver injury and oxidative stress seen in chronic hepatitis C[39]. Zinc plays an important role in the redox process as a signal molecule and second messenger.
Decrease of supportive nutrients such as zinc have been documented in patients with viral or alcoholic liver disease. These markers may contribute to the monitoring the degree of liver damage, the response to antiviral therapies and to the design of new therapeutic strategies[40]. Effects of zinc in the treatment of chronic hepatitis C are produced via immunological reactions, antiviral defence mechanisms and the role of zinc as an antioxidant[41]. Furthermore, Yuasa et al[42] have shown that zinc substitution negatively influences HCV replication. Zinc supplementation thus appears to offer a novel approach to the development of future strategies for the treatment of intractable chronic hepatitis C.
Leucopenia or thrombocytopenia is often found in elderly patients with chronic hepatitis C with severe fibrosis, and in many such cases, the IFN therapy must be discontinued due to side effects.
According to the results of a study in which zinc was administered in applying IFN and RBV therapy to cases of chronic hepatitis C with a tendency toward zinc deficiency to assess its effects on cytopenia, zinc served to protect against a reduction in white blood cells or platelets and thus effectively inhibited side effects.
The reduction in the number of peripheral blood cells due to IFN therapy seems to be caused by inhibition of the hematopoietic function of bone marrow. When RBV is combined with IFN therapy, hemolytic anemia due to the accumulation of RBV in red blood cells also seems to cause such a reduction. In cases of chronic hepatitis C with severe fibrosis, the number of blood cells tends to be already low before the administration of IFN or RBV, and therefore how to prevent the reduction in blood cells as a side effect is important.
Nagamine et al[43] conducted a basic study on the activity of IFN-α in U937 cells in order to elucidate whether zinc would enhance the action of interferon. They found that zinc chloride and polaprezinc increased IFNAR mRNA by 30% to 40%, whereas monotherapy of L-carnosine had no such effect, suggesting that zinc enhanced the action of interferon and induced the production of anti-viral proteins. Hence, many cases of liver disease are accompanied by complaints of symptoms in the mouth such as dysgeusia, dry mouth and stomatitis when treated with PEG-IFN/RBV. Zinc supplement seems to be effective against oral mucosa disorders in IFN therapy treatment.
A new antiviral drug called DAA became covered by the public health insurance system in Japan. Hence, the treatment of choice for cases with a high quantity of genotype 1 virus is likely to be DAA + PEG-IFN α-2b + RBV combination therapy (the “3-drug therapy”). However, it has been reported that this therapy causes side effects such as severe hemoglobin reduction or severe rash, and many side effects in elderly patients.
Zinc supplementation to reduce such side effects may be the key to developing more effective anti-viral therapies. As this paper has suggested, the administration of zinc in many clinical cases requires further study. Prospective double-blind studies with large sample sizes are necessary.
Footnotes
Peer reviewers: Heitor Rosa, Professor, Department of Gastroenterology and Hepatology, Federal University School of Medicine, Rua 126 n.21, Goiania-GO 74093-080, Brazil; Natalia A Osna, MD, PhD, Liver Study Unit, Research Service (151), VA Medical Center, 4101 Woolworth Avenue, Omaha, NE 68105, United States
S- Editor Cheng JX L- Editor A E- Editor Zhang DN
1. Granick S. Iron metabolism and hemochromatosis. Bull N Y Acad Med. 1949;25:403–428. [PubMed]
2. Evans GW, Bubois RS, Hambidge KM. Wilson’s disease: identification of an abnormal copper-binding protein. Science. 1973;181:1175–1176. [PubMed]
3. Fredricks RE, Tanaka KR, Valentine WN. Zinc in human blood cells: normal values and abnormalities associated with liver disease. J Clin Invest. 1960;39:1651–1656. [PMC free article] [PubMed]
4. Herring WB, Leavell BS, Paixo LM, Yoe JH. Trace metals in human plasma and red blood cells. A study of magnesium, chromium, nickel, copper and zinc. I. Obser- vations of normal subjects. Am J Clin Nutr. 1960;8:846–854. [PubMed]
5. Herring WB, Leavell BS, Paixao LM, Yoe JH. Trace metals in human plasma and red blood cells. A study of magnesium, chromium, nickel, copper and zinc. II. Observations of patients with some hematologic diseases. Am J Clin Nutr. 1960;8:855–863. [PubMed]
6. Vikbladh I. Studies on zinc in blood II. Scand J Clin Lab Invest. 1951;3 Suppl 2:1–74. [PubMed]
7. Bartholomay AF, Robin ED, Vallee RL, Wacker WE. Zinc metabolism in hepatic dysfunction. I. Serum zinc concentrations in Laënnec’s cirrhosis and their validation by sequential analysis. N Engl J Med. 1956;255:403–408. [PubMed]
8. Sullivan JF, Jetton MM, Burch RE. A zinc tolerance test. J Lab Clin Med. 1979;93:485–492. [PubMed]
9. Grüngreiff K, Abicht K, Kluge M, Presser HJ, Franke D, Kleine FD, Klauck S, Diete U. Clinical studies on zinc in chronic liver diseases. Z Gastroenterol. 1988;26:409–415. [PubMed]
10. Solis-Herruzo J, De Cuenca B, Muñoz-Rivero MC. Intestinal zinc absorption in cirrhotic patients. Z Gastroenterol. 1989;27:335–338. [PubMed]
11. Bode JC, Hanisch P, Henning H, Koenig W, Richter FW, Bode C. Hepatic zinc content in patients with various stages of alcoholic liver disease and in patients with chronic active and chronic persistent hepatitis. Hepatology. 1988;8:1605–1609. [PubMed]
12. Milman N, Laursen J, Pødenphant J, Asnaes S. Trace elements in normal and cirrhotic human liver tissue. I. Iron, copper, zinc, selenium, manganese, titanium and lead measured by X-ray fluorescence spectrometry. Liver. 1986;6:111–117. [PubMed]
13. Nandi SS, Chawla YK, Nath R, Dilawari JB. Serum and urinary zinc in fulminant hepatic failure. J Gastroenterol Hepatol. 1989;4:209–213. [PubMed]
14. Ebara M, Fukuda H, Hatano R, Yoshikawa M, Sugiura N, Saisho H, Kondo F, Yukawa M. Metal contents in the liver of patients with chronic liver disease caused by hepatitis C virus. Reference to hepatocellular carcinoma. Oncology. 2003;65:323–330. [PubMed]
15. Ebara M, Fukuda H, Saisho H. The copper/zinc ratio in patients with hepatocellular carcinoma. J Gastroenterol. 2003;38:104–105. [PubMed]
16. Moriyama M, Matsumura H, Fukushima A, Ohkido K, Arakawa Y, Nirei K, Yamagami H, Kaneko M, Tanaka N, Arakawa Y. Clinical significance of evaluation of serum zinc concentrations in C-viral chronic liver disease. Dig Dis Sci. 2006;51:1967–1977. [PubMed]
17. Han DS, Hahm B, Rho HM, Jang SK. Identification of the protease domain in NS3 of hepatitis C virus. J Gen Virol. 1995;76(Pt 4):985–993. [PubMed]
18. Lohmann V, Koch JO, Bartenschlager R. Processing pathways of the hepatitis C virus proteins. J Hepatol. 1996;24:11–19. [PubMed]
19. Stempniak M, Hostomska Z, Nodes BR, Hostomsky Z. The NS3 proteinase domain of hepatitis C virus is a zinc-containing enzyme. J Virol. 1997;71:2881–2886. [PMC free article] [PubMed]
20. Schregel V, Jacobi S, Penin F, Tautz N. Hepatitis C virus NS2 is a protease stimulated by cofactor domains in NS3. Proc Natl Acad Sci USA. 2009;106:5342–5347. [PubMed]
21. Tellinghuisen TL, Marcotrigiano J, Gorbalenya AE, Rice CM. The NS5A protein of hepatitis C virus is a zinc metalloprotein. J Biol Chem. 2004;279:48576–48587. [PubMed]
22. Loguercio C, De Girolamo V, Federico A, Feng SL, Cataldi V, Del Vecchio Blanco C, Gialanella G. Trace elements and chronic liver diseases. J Trace Elem Med Biol. 1997;11:158–161. [PubMed]
23. Hoofnagle JH, Mullen KD, Jones DB, Rustgi V, Di Bisceglie A, Peters M, Waggoner JG, Park Y, Jones EA. Treatment of chronic non-A,non-B hepatitis with recombinant human alpha interferon. A preliminary report. N Engl J Med. 1986;315:1575–1578. [PubMed]
24. Davis GL, Balart LA, Schiff ER, Lindsay K, Bodenheimer HC, Perrillo RP, Carey W, Jacobson IM, Payne J, Dienstag JL. Treatment of chronic hepatitis C with recombinant interferon alfa. A multicenter randomized, controlled trial. Hepatitis Interventional Therapy Group. N Engl J Med. 1989;321:1501–1506. [PubMed]
25. Di Bisceglie AM, Martin P, Kassianides C, Lisker-Melman M, Murray L, Waggoner J, Goodman Z, Banks SM, Hoofnagle JH. Recombinant interferon alfa therapy for chronic hepatitis C. A randomized, double-blind, placebo-controlled trial. N Engl J Med. 1989;321:1506–1510. [PubMed]
26. Nakamura H, Ito H, Ogawa H, Takeda A, Kanazawa S, Kuroda T, Yamamoto M, Enomoto H, Kimura Y, Zenda S, et al. Initial daily interferon administration can gain more eradication of HCV-RNA in patients with chronic hepatitis C, especially with serum intermediate viral load. Hepatogastroenterology. 1999;46:1131–1139. [PubMed]
27. Iino S, Tomita E, Kumada H, Suzuki H, Toyota J, Kiyosawa K, Tanikawa K, Sata M, Hayashi N, Kakumu S, et al. Impact of daily high-dose IFNalpha-2b plus ribavirin combination therapy on reduction of ALT levels in patients with chronic hepatitis C with genotype 1 and high HCV RNA levels. Hepatol Res. 2005;31:88–94. [PubMed]
28. Tsubota A, Arase Y, Someya T, Suzuki Y, Suzuki F, Saitoh S, Ikeda K, Akuta N, Hosaka T, Kobayashi M, et al. Early viral kinetics and treatment outcome in combination of high-dose interferon induction vs. pegylated interferon plus ribavirin for naive patients infected with hepatitis C virus of genotype 1b and high viral load. J Med Virol. 2005;75:27–34. [PubMed]
29. Fried MW, Shiffman ML, Reddy KR, Smith C, Marinos G, Gonçales FL, Häussinger D, Diago M, Carosi G, Dhumeaux D, et al. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med. 2002;347:975–982. [PubMed]
30. Manns MP, McHutchison JG, Gordon SC, Rustgi VK, Shiffman M, Reindollar R, Goodman ZD, Koury K, Ling M, Albrecht JK. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet. 2001;358:958–965. [PubMed]
31. Nagamine T, Takagi H, Hashimoto Y, Takayama H, Shimoda R, Nomura N, Suzuki K, Mori M, Nakajima K. The possible role of zinc and metallothionein in the liver on the therapeutic effect of IFN-alpha to hepatitis C patients. Biol Trace Elem Res. 1997;58:65–76. [PubMed]
32. Takagi H, Nagamine T, Abe T, Takayama H, Sato K, Otsuka T, Kakizaki S, Hashimoto Y, Matsumoto T, Kojima A, et al. Zinc supplementation enhances the response to interferon therapy in patients with chronic hepatitis C. J Viral Hepat. 2001;8:367–371. [PubMed]
33. Murakami Y, Koyabu T, Kawashima A, Kakibuchi N, Kawakami T, Takaguchi K, Kita K, Okita M. Zinc supplementation prevents the increase of transaminase in chronic hepatitis C patients during combination therapy with pegylated interferon alpha-2b and ribavirin. J Nutr Sci Vitaminol ( Tokyo) 2007;53:213–218. [PubMed]
34. Boyett JD, Sullivan JF. Zinc and collagen content of cirrhotic liver. Am J Dig Dis. 1970;15:797–802. [PubMed]
35. Himoto T, Hosomi N, Nakai S, Deguchi A, Kinekawa F, Matsuki M, Yachida M, Masaki T, Kurokochi K, Watanabe S, et al. Efficacy of zinc administration in patients with hepatitis C virus-related chronic liver disease. Scand J Gastroenterol. 2007;42:1078–1087. [PubMed]
36. Matsuoka S, Matsumura H, Nakamura H, Oshiro S, Arakawa Y, Hayashi J, Sekine N, Nirei K, Yamagami H, Ogawa M, et al. Zinc supplementation improves the outcome of chronic hepatitis C and liver cirrhosis. J Clin Biochem Nutr. 2009;45:292–303. [PMC free article] [PubMed]
37. Takahashi M, Saito H, Higashimoto M, Hibi T. Possible inhibitory effect of oral zinc supplementation on hepatic fibrosis through downregulation of TIMP-1: A pilot study. Hepatol Res. 2007;37:405–409. [PubMed]
38. Jain SK, Pemberton PW, Smith A, McMahon RF, Burrows PC, Aboutwerat A, Warnes TW. Oxidative stress in chronic hepatitis C: not just a feature of late stage disease. J Hepatol. 2002;36:805–811. [PubMed]
39. Wang T, Weinman SA. Causes and consequences of mitochondrial reactive oxygen species generation in hepatitis C. J Gastroenterol Hepatol. 2006;21 Suppl 3:S34–S37. [PubMed]
40. Loguercio C, Federico A. Oxidative stress in viral and alcoholic hepatitis. Free Radic Biol Med. 2003;34:1–10. [PubMed]
41. Overbeck S, Rink L, Haase H. Modulating the immune response by oral zinc supplementation: a single approach for multiple diseases. Arch Immunol Ther Exp ( Warsz) 2008;56:15–30. [PubMed]
42. Yuasa K, Naganuma A, Sato K, Ikeda M, Kato N, Takagi H, Mori M. Zinc is a negative regulator of hepatitis C virus RNA replication. Liver Int. 2006;26:1111–1118. [PubMed]
43. Nagamine T, Nakajima K, Takada H, Sekine Y, Suzuki K. Induction of type 1 interferon receptor by zinc in U937 cells. Cytokine. 2009;46:346–350. [PubMed]
Articles from World Journal of Gastroenterology : WJG are provided here courtesy of
Baishideng Publishing Group Co., Ltd.